Real-world experience with first-line pembrolizumab plus chemotherapy in Vietnamese patients with stage IV esophageal squamous cell carcinoma
In this Vietnamese cohort, pembrolizumab plus chemotherapy showed a manageable safety profile and recurrence patterns consistent with those reported internationally. These findings add region-specific real-world evidence and underline the importance of broader multi-center studies with longer follow-up to inform practice in advanced ESCC.
Authors
- Quang Le (ORCID: https://orcid.org/0000-0002-5124-2398)
- Huy Le Trinh (ORCID: https://orcid.org/0000-0001-9598-5962)
- Thuan V. Tran (ORCID: https://orcid.org/0000-0002-5839-0895)
- Kien Hoang Le
- Phuong Thu Nguyen
- Giang Huong T. Nguyen
- Giap Ngoc Hoang
Institutions
- Vietnam National University Ho Chi Minh City (VN)
- Hanoi Medical University (VN)
- Vietnam National Children's Hospital (VN)
- Bạch Mai Hospital (VN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3389/fimmu.2026.1713860
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00